Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - metformine hydrochloride, dapagliflozin propaandiol monohydraat - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo is geïndiceerd bij volwassenen voor de behandeling van type 2 diabetes mellitus als een aanvulling op dieet en lichaamsbeweging:• bij patiënten die onvoldoende gecontroleerd op hun maximaal toelaatbare dosis van metformine alleen • in combinatie met andere geneesmiddelen voor de behandeling van diabetes bij patiënten die onvoldoende aangestuurd met metformine en deze geneesmiddelen• bij patiënten die al worden behandeld met de combinatie van dapagliflozin en metformine als afzonderlijke tabletten. voor het onderzoek naar de resultaten met betrekking tot de combinatie van therapieën, effecten op de glycemische controle en cardiovasculaire gebeurtenissen, en de bestudeerde populaties, zie punt 4. 4, 4. 5 en 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - fasenra is aangegeven als een add-on onderhoud van behandeling bij volwassen patiënten met ernstige eosinofiele astma onvoldoende beheerste, ondanks de hoge dosis inhalatiecorticosteroïden plus langwerkende β-agonisten.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - natrium zirkonium cyclosilicate - hyperkaliëmie - alle andere therapeutische producten - lokelma is geïndiceerd voor de behandeling van hyperkaliëmie bij volwassen patiënten.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - longaandoening, chronisch obstructief - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemie, lymfocytisch, chronisch, b-cel - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastische middelen - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.